{
  "ticker": "CD1",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02978048",
  "id": "02978048",
  "pages": 8,
  "price_sensitive": false,
  "date": "20250807",
  "time": "1447",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmz7nxz8fhfb.pdf",
  "summary": "Here\u2019s the extracted material information for trading/capital markets decisions, formatted concisely:  \n\n### **Quarterly Report (Appendix 4C) Summary**  \n**Key Financials (CD1 as of 30 June 2025):**  \n- **NTA per unit**: $0.87 (post-tax)  \n- **Quarterly NTA Return**: -5.4% (FX losses due to AUD strengthening)  \n- **Cash Balances**:  \n  - Fund-level cash: **A$1.63m**  \n  - LP cash (CD1 interest): **US$3.16m**  \n  - Underlying funds (CD1 interest): **US$12.03m**  \n\n**Portfolio Highlights:**  \n- **Remaining portfolio companies**: 18 (13 active, 5 impaired but holding residual value).  \n- **Q2 Realisations**:  \n  - **Gross MOIC**: 2.23x (average)  \n  - Two exited companies: **GetixHealth** (healthcare IT) and **IDMWorks** (IAM software).  \n- **Market Conditions**:  \n  - Softened private equity sentiment (tariffs, high rates, geopolitics).  \n  - Secondary market growth (2025 forecast: >US$220bn volume).  \n\n**Capital Return Potential**:  \n- Assessing **excess capital return** to CD1/CD3 unitholders (follow-up pending).  \n\n**Performance Metrics:**  \n- **Since inception IRR**: 11.7% p.a.  \n- **Discount to NTA**: Unit price **$0.535** vs. NTA **$0.87** (38.5% discount).  \n\n*Omitted: Boilerplate, governance details, non-material operational updates.*",
  "usage": {
    "prompt_tokens": 5343,
    "completion_tokens": 369,
    "total_tokens": 5712,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-07T05:25:40.871266"
}